微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 21.62% | 48.69% | -12.12% | 136/158 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 24.6% | 6.49% | 62.57% | 125/158 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 15.13% | -6.04% | -4.93% | 144/158 | 50.33% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 15.92% | -11.86% | 9.47% | 140/158 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 14.54% | -8.28% | -37.07% | 142/158 | 14.78% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 23.1% | 94.27% | 43.45% | 127/158 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 16.1% | -28.44% | -10.82% | 142/158 | 51.59% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 18.06% | -42.06% | 13.93% | 140/158 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 15.85% | -58.41% | 33.29% | 141/158 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 11.89% | -70.03% | -47.16% | 140/158 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 22.5% | -49.34% | -27.79% | 134/158 | 51.32% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.16% | -37.05% | -18.23% | 117/158 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 38.11% | -26.79% | -3.93% | 108/158 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 39.67% | -21.8% | -10.69% | 98/158 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 44.42% | -23.65% | -10.27% | 91/158 | 53.52% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 49.5% | -18.38% | -4.91% | 80/158 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.06% | -14.73% | 2.61% | 77/158 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 50.73% | -17.09% | -12.8% | 76/158 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 58.18% | -15.27% | -4.07% | 66/158 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 60.65% | -14.95% | -0.66% | 53/158 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 61.05% | -13.46% | -0.22% | 56/158 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 61.19% | -20.59% | -10.89% | 48/158 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 68.67% | -6.06% | -3.71% | 42/158 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 71.31% | -3.79% | 1.08% | 30/158 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 70.55% | -0.71% | -8.44% | 30/158 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 77.06% | 8.04% | 5.42% | 21/158 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.09% | 2.34% | -1.38% | 32/158 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 74.12% | 4.82% | 4.31% | 18/158 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 71.06% | 1.94% | -0.37% | 27/158 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 71.32% | -0.28% | -0.15% | 21/158 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 71.42% | 9.06% | 1.01% | 33/158 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 70.71% | 1.95% | 1.43% | 21/158 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.71% | -2.63% | -2.53% | 19/158 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 71.52% | 9.82% | 9.2% | 18/158 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 65.49% | 1.24% | -5.57% | 31/158 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.35% | 5.61% | -3.13% | 17/158 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 71.59% | 11.56% | 9.94% | 15/158 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 65.12% | 1.26% | 0.66% | 18/158 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 64.69% | -3.16% | -1.49% | 25/158 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 65.67% | 2.46% | 2.34% | 17/158 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 64.17% | 3.51% | -0.22% | 21/158 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 64.31% | 0.98% | -3.72% | 15/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |